Surrozen (SRZN) Other Operating Expenses (2020 - 2023)

Surrozen (SRZN) posted quarterly Other Operating Expenses of $40000.0 for Q4 2023, down 97.34% quarter-over-quarter from $1.5 million in Q3 2023.

Surrozen (SRZN) Other Operating Expenses (2020 - 2023) Analysis & Trends

Surrozen's Other Operating Expenses history runs 3 years deep, the most recent figure standing at $40000.0 for Q4 2023.

In Q4 2023, Other Operating Expenses changed N/A year-over-year to $40000.0; the TTM figure through Sep 2024 stood at $40000.0 (down 98.53% YoY), while the FY2023 annual figure was $2.8 million, changed N/A from the prior year.
Other Operating Expenses for Q4 2023 stood at $40000.0, down from $1.5 million in the prior quarter.
The five-year high for Other Operating Expenses was $1.5 million in Q3 2023, with the low at -$39.6 million in Q3 2021.
The 3-year median for Other Operating Expenses is $40000.0 (2023), against an average of -$9.4 million.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Surrozen	281.63 Mn	281.63 Mn	-

Download Data